For the study, researchers from NYU Langone Medical Center in New York analyzed and compared bacteria collected from 361 mouthwash samples from participants who developed pancreatic cancer and 371 people of similar demographics who did not. All participants were involved with ongoing cancer-risk studies. All study participants were healthy when sample taking began. The participants were monitored for nearly a decade.
Through their analysis, researchers found that men and women whose oral microbiomes contained Porphyromonas gingivalis had a 59 percent greater risk of developing pancreatic cancer than participants whose samples did not suggest the presence of this bacterium. Also, participants with oral microbiomes containing Aggregatibacter actinomycetemcomitans were at least 50 percent more likely to develop pancreatic cancer.
The study’s senior investigator, Jiyoung Ahn, PhD, an epidemiologist and associate professor at NYU Langone, said, “Our study offers the first direct evidence that specific changes in the microbial mix in the mouth — the oral microbiome — represent a likely risk factor for pancreatic cancer…these bacterial changes in the mouth could potentially show us who is most at risk of developing pancreatic cancer.”
More articles on quality:
CDC to launch investigation into youth football
CMS delays overall hospital star ratings release: 4 things to know
A physician perspective on the opioid crisis: Q&A with Dr. James Campbell
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
